United States Liquid Biopsy Market Analysis

The United States Liquid Biopsy Market value is foreseen to be around US$ 3.68 Billion by 2032, with a CAGR of 14.83% from 2024 to 2032. According to Renub Research, the market was valued at US$ 1.06 Billion in 2023.

Liquid biopsy is a prevalent non-invasive diagnostic approach that detects biomarkers in blood or urine, primarily used for cancer detection and monitoring. Its versatility extends beyond oncology, encompassing prenatal testing, infectious diseases, and organ transplant monitoring. This innovative method revolutionizes patient care by facilitating timely and personalized treatment strategies due to ongoing technological advancements.

United States Liquid Biopsy Growth Drivers

1. Growing Cases of Cancer: The National Institutes of Health (NIH) estimates that around 2.0 million people in the U.S. will be diagnosed with cancer in 2023. The high incidence of cancers such as breast cancer (projected 297,790 new cases), prostate cancer (288,300), and lung cancer (238,340) is significantly driving market growth. Liquid biopsy's ability to evaluate cancer-related alerts through biological fluids has generated considerable interest in recent years.
2. Increasing Acceptance of Non-Invasive Techniques: Liquid biopsy represents a novel approach for minimally invasive molecular diagnostics. In 2018, of approximately 9.6 million inpatient primary operating room procedures, 11.2% were minimally invasive, demonstrating the growing trend towards less invasive diagnostic options, which will further boost the liquid biopsy market.
3. Emphasis on Companion Diagnostics: The increased use of companion diagnostics, which help determine the suitability and effectiveness of specific drugs for patients, is enhancing market growth. For instance, in January 2023, the FDA approved FoundationOne Liquid CDx to identify ROS1-positive non-small cell lung cancer (NSCLC).
4. Progress in Technology: Advancements such as next-generation sequencing (NGS) drive innovation in liquid biopsy, allowing for precise evaluation of circulating tumor cells (CTCs) and cell-free DNA (cfDNA). This improves cancer detection and monitoring, propelling market growth. For example, Illumina Inc. introduced TruSight™ Oncology 500 ctDNA v2 in November 2023 to expand non-invasive genomic profiling.

Breast Cancer Focus

Breast cancer is expected to emerge as a significant area of concern within the United States liquid biopsy market, driven by the demand for less invasive early detection and monitoring techniques. Approximately 13% of American women are projected to develop invasive breast cancer in their lifetime.

United States Liquid Biopsy Company News

Leading companies in the U.S. liquid biopsy market include Thermo Fisher Scientific Inc., Roche Diagnostics, Bio-Rad Laboratories Inc., Biocept, Inc., Biocartis, Myriad Genetics, Inc., Exact Sciences (Genomic Health), NeoGenomics Laboratories, and Quest Diagnostics Inc. Recent notable developments include:

·        October 2023: The FDA approved Foundation Medicine's FoundationOne®CDx and FoundationOne®Liquid CDx as companion diagnostics for Pfizer’s BRAFTOVI® and MEKTOVI® to detect BRAF V600E mutation in metastatic non-small cell lung cancer.

·        October 2023: Researchers at UCLA secured a US$ 4.6 Million grant from the National Cancer Institute to enhance liquid biopsy technologies for early lung cancer detection.

·        October 2023: Exact Sciences announced its intention to utilize its acquisition of Resolution Bioscience to enter the next-generation sequencing-based liquid biopsy market.

·        April 2023: Quest Diagnostics announced its agreement to acquire Haystack Oncology, a startup specializing in early-stage liquid biopsy testing for detecting residual or recurring cancer, for up to US$ 450 Million.

·        April 2023: QIAGEN introduced the QIAseq Targeted cfDNA Ultra Panels for cancer and disease research, expediting the conversion of cfDNA liquid-biopsy samples to NGS-ready libraries in under eight hours.

·        March 2023: Thermo Fisher Scientific expanded its molecular diagnostics portfolio by launching new liquid biopsy assays aimed at enhancing cancer detection and monitoring capabilities.

Market Breakdown

·        Cancer Types:

1.     Lung Cancer

2.     Breast Cancer

3.     Colorectal Cancer

4.     Prostate Cancer

5.     Liver Cancer

6.     Other Cancer

·        Products:

1.     Kits & Reagents

2.     Platforms & Instruments

3.     Services

·        Application:

1.     Early Diagnosis

2.     Patient Monitoring

3.     Recurrence Monitoring

·        Biomarkers:

1.     Circulating Tumor Cells (CTCs)

2.     Circulating Tumor DNA (ctDNA)

3.     Extracellular Vesicles (EVs)

·        Sample Types:

1.     Blood

2.     Urine

3.     Others

·        End-Users:

1.     Hospitals & Laboratories

2.     Governments & Academic Research Centers

Company Analysis

1. Thermo Fisher Scientific Inc.
2. Roche Diagnostics
3. Bio-Rad Laboratories Inc.
4. Biocept, Inc.
5. Biocartis
6. Myriad Genetics, Inc.
7. Exact Sciences (Genomic Health)
8. NeoGenomics Laboratories
9. Quest Diagnostic Inc.

About Renub Research

Renub Research is a Market Research and Information Analysis company with over 15 years of experience in research, survey, and consulting. We empower companies to make informed business decisions regarding strategy, organization, operations, technology, and mergers & acquisitions. With more than 9,000 syndicated reports and over 750 custom research projects, we supply data to leading organizations such as EMIS, Bloomberg, and Thomson Reuters.

Media Contact

·        Company Name: Renub Research

·        Contact Person: Rajat Gupta, Marketing Manager

·        Phone: +1-478-202-3244 | +91-120-421-9822 (IND)

·        Address: 225 Kristie Ln, Roswell, GA 30076

·        Email: info@renub.com

·        LinkedIn: Renub Research LinkedIn

·        Website: www.renub.com